Olivier Pâris

Associate, Paris



Olivier Pâris is an associate in the Corporate/Mergers & Acquisitions department of White & Case in Paris.

He is involved in corporate transactions in all manner of M&A, including public and private M&A deals, sales and joint ventures primarily belonging to the jumbo-cap to mid-cap market segments. Olivier also advises clients in connection with corporate governance, market abuse and insider dealing issues.

Olivier is at ease working on domestic and cross-border mergers and acquisitions on behalf of multinational clients, including investment banks, entrepreneurs, industrials, listed, and non-listed companies, from all sectors, in particular in the automotive, financial, banking and energy and infrastructure sectors.

Prior to joining White & Case in 2020, Olivier practiced in the Paris office of a Magic Circle law firm for six years.

Bars and Courts
Post-Master's Degree
Financial & Business Law
University of Paris XI Sceaux
Master's Degree
Business Law
Panthéon-Assas University
Banking and Tax law
Panthéon-Assas University
Master's Degree
Corporate Finance
École supérieure de commerce de Reims

(NEOMA Business School)



Olivier has advised on significant corporate transactions, including:

Representation of Sodexo on the spin-off of its Benefits and Rewards Services business, under the new brand name Pluxee, and its listing on Euronext Paris

Pegasus Entrepreneurs and its sponsors Tikehau Capital, Financière Agache, CEO Pierre Cuilleret, Jean-Pierre Mustier and Diego De Giorgi in connection with its de-SPACing with FL Entertainment, a global entertainment group comprising Banijay Group and Betclic Everest Group, that will result in the listing of FL Entertainment on Euronext Amsterdam.

Representation of Biosynex, on:

  • the takeover offer for Theradiag and the merger between Biosynex and Theradiag;
  • the acquisition of ProciseDX in the United States;
  • the acquisition of the eye care business of Laboratoires Innoxa;
  • the acquisition of DOC2U;
  • Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, for the all-cash tender offer for US$.45 per share;
  • the acquisition of Laboratorios Rhogen in Spain;
  • the acquisition of Bigix Pharma in Italy;
  • the acquisition of Medkoncept in Demark;
  • the acquisition of BHR Pharmaceuticals Ltd in the United Kingdom;
  • the acquisition of "Para'kito", the European leader in the prevention and treatment of mosquito bites with 100% natural formulas, its active ingredients and its IP (patents and trademarks);
  • the acquisition of Enalees' business going concern relating to medical diagnostic products;
  • the sale of a business going concern to ELITech Microbio relating to medical diagnostic products.

RTL Group in connection with the proposed combination between Groupe TF1 and Groupe M6.

Caisse des Dépôts et Consignations on the sale of its minority stakes held in three biomass plants (Kogeban, Cogénération Biomasse d'Estrées-Mons et Cogénération Biomasse de Novillars) to PEARL Infrastructure Capital.

Idex on its acquisition of a biomass power generation plant and its operating company*.

Engie on the agreement with EDPR to create a co-controlled 50/50 joint-venture in fixed and floating offshore wind*.

Engie New Business on the investment in tiko Energy Solutions AG*.

RP Global on the sale of portfolios companies of wind farms projects to EDPR*.

SIX Group AG in relation to the signing of a strategic partnership with Worldline SA. This operation consisted in the contribution by SIX Group of its payment services division to Worldline SA*.

Sonnedix on the acquisition of portfolio companies owning and operating photovoltaic power plants*.

BNP Paribas and BNP Paribas Personal Finance, on the acquisition of OPEL/Vauxhall's captive financing activities and the set-up of a long-term strategic partnership with PSA*.

*Transactions worked on prior to joining White & Case